Sequence: CRWRWKCCKK
| Experiment Id | EXP002415 |
|---|---|
| Paper | The promoted delivery of RRM2 siRNA to vascular smooth muscle cells through liposome-polycation-DNA |
| Peptide | CyLoP-1 (CCPs) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 80 µg CPPs per formulation (post-insertion) |
| Rna Concentration | 200 nM siRNA (in vitro) |
| Mixing Ratio | CLPD (CPP-conjugated LPD) vs NCLPD controls |
| Formulation Format | CPP-conjugated liposome–polycation–DNA complex (CLPD) |
| Formulation Components | DOTAP/cholesterol liposomes + protamine + calf thymus DNA + DSPE-PEG2000-Mal + CCPs |
| Size Nm | 150.00 |
| Zeta Mv | 23.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Primary human aortic smooth muscle cells (HASMCs) |
| Animal Model | |
| Administration Route | cell culture incubation |
| Output Type | gene knockdown; migration and proliferation inhibition |
| Output Value | ~80% RRM2 mRNA knockdown; ~75% protein reduction |
| Output Units | |
| Output Notes | Flow cytometry and CFPE-labeled liposomes show enhanced uptake; strong functional RNAi |
| Toxicity Notes | Minimal cytotoxicity; CCPs alone non-toxic |
| Curation Notes |